Dr Sumeray has over 17 years’ experience in the pharmaceutical, medical devices and biotech sectors both in the US and UK. Most recently, he spent approximately five years as Chief Medical Officer at Aegerion Pharmaceuticals, a US-based orphan disease biotech company. At Aegerion, he had clinical development, medical affairs and pharmacovigilance responsibility for the global approval and launch of a new treatment for a serious and rare genetic disease. Mark led clinical and scientific interactions with health authorities globally, and engaged at senior level with the US Food and Drug Administration (“FDA”). His role also encompassed negotiations with payers and developing a market access strategy. In addition, Mark was the key company presenter at a Scientific Advice Group meeting of the Committee for Medicinal Products for Human Use (“CHMP”) in Europe.
Prior to working at Aegerion, Mark was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He also worked at The Medicines Company, a US based biopharmaceutical company focused on acute care hospital products, and at Ethicon, a J&J medical device company, where he was responsible for the clinical group.
Mark spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology, having qualified as a medical doctor at the University of London.